Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27161900 | 0.94 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL12565582 | 0.92 | ALDH1A1 (0.51) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL16370059 | 0.90 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL20465366 | 0.88 | ALDH1A1 (0.47) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL15581005 | 0.88 | ALDH1A1 (0.60) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL621696 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL11015123 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL2032918 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL16699608 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL17430945 | 0.84 | MAOB (0.45) | ALDH1A1NPC1RAB9AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417515-B | 2-methyl-2-carbobenzoxy-1, 3-propanediol modified PBAT material and preparation method thereof | 康辉新材料科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117417515-A | 2-methyl-2-carbobenzoxy-1, 3-propanediol modified PBAT material and preparation method thereof | 康辉新材料科技有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-109054010-B | Imidazole ring modified acid-sensitive polycarbonate material and preparation and application thereof | 沈阳信达泰康医药科技有限公司 | 2022-08-16 | — | — | CN | claimed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4531923-A1 | SMALL MOLECULE CONJUGATED CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025024329-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | disclosed |
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| CN-117417515-B | 2-methyl-2-carbobenzoxy-1, 3-propanediol modified PBAT material and preparation method thereof | 康辉新材料科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117417515-B | 2-methyl-2-carbobenzoxy-1, 3-propanediol modified PBAT material and preparation method thereof | 康辉新材料科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117417515-B | 2-methyl-2-carbobenzoxy-1, 3-propanediol modified PBAT material and preparation method thereof | 康辉新材料科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-6399666-B1 | FOR MICROCIRCUIT; DECOMPOSABLE POLYMER AND DIELECTRIC | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2002-06-04 | — | — | US | disclosed |
| EP-1123935-A2 | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | MEDIVIR AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| EP-0988304-B1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| EP-0942916-A2 | NUCLEOSIDES | Medivir Aktiebolag (SE) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999000440-A1 | SYNTHESIS OF A DENDRITIC POLYALCOHOL | PERSTORP AB (SE) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998021223-A1 | NUCLEOSIDES | MEDIVIR AB (SE) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | MAPK13, MAPK12, MAP3K13 | ALDH1A1 3887/4885KMT2A 3281/4885TDP1 2011/4885 |
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | TLR3, TLR9, ADAR | ALDH1A1 2968/4885KMT2A 1037/4885TDP1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.